SBIA
UTHR icon

Sheaff Brock Investment Advisors’s United Therapeutics UTHR Stock Holding History

Sheaff Brock Investment Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,864
Closed -$208K – 641
2016
Q1 		$208K Buy
+1,864
New +$236K 0.03% 481

Other funds holding UTHR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Sheaff Brock Investment Advisors's UTHR Position: Q2 2016 in Review

Sheaff Brock Investment Advisors sold out of United Therapeutics (UTHR) in Q2 2016, closing a stake of 1,864 shares — an estimated $208K sold.

Sheaff Brock Investment Advisors first reported a position in UTHR in Q1 2016 and held it in 1 quarter. The position peaked at $208K in Q1 2016. 384 funds tracked by Wall St. Rank hold UTHR as of Q2 2016.

  • Sheaff Brock Investment Advisors reported no remaining United Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Sheaff Brock Investment Advisors sold 1,864 United Therapeutics shares in Q2 2016, an estimated $208K.
  • Sheaff Brock Investment Advisors first reported a position in United Therapeutics in Q1 2016 and held it in 1 quarter.
  • Sheaff Brock Investment Advisors's United Therapeutics position peaked at $208K in Q1 2016.
  • 384 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2016.

Based on Sheaff Brock Investment Advisors's 13F filing for Q2 2016, filed 5 Aug 2016.